Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Willow Biosciences Inc T.WLLW

Alternate Symbol(s):  CANSF

Willow Biosciences Inc. is a Canada-based biotechnology company. The Company develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Its FutureGrown biotechnology platform allows production with sustainability at its core. Its commercial product, Cannabigerol CBG, which is a cannabinoid that has anti-microbial, anti-inflammatory, and antioxidant properties. It also offers BioOxi, a bio-oxidation technology platform. By leveraging BioOxi, commercial partners can revolutionize manufacturing of oxygenated and hydroxylated functional ingredients, such as steroids, polyphenols, oxyterpenes and certain other targeted ingredients produced from such methods. It is also developing BioOxi-based process for production of the generic active pharmaceutical ingredient (API), hydrocortisone, and its derivatives. Its other pipeline products include Ursodeoxycholic acid (UCAC), Astaxanthin, B-carotene and others.


TSX:WLLW - Post by User

Bullboard Posts
Comment by BeeInveSTINGon Apr 23, 2020 7:56pm
168 Views
Post# 30947481

RE:CHRIS SAVILE

RE:CHRIS SAVILE
I appreciate your response. I am in NO WAY attempting to discredit Dr. Savile's merit, however... the C&P from Willow's website doesn't quite answer my question. I don't wish to scoff at their clarification. Moving to scale-up "ahead of initial expectations" great news!!!" Relocation of resources..." that's business "reduced head count..." sure. My concern is about the bigger picture. Willow is a Bioscience company, which is publicly traded in a burgeoning albeit very temperamental market space. These characteristics combined makes me all the more apprehensive about blindly accepting key management changes. Especially when my previous interpretation was that the incumbent was in part vital to the operation. I am NOT hinting that their is anything shady going on. I just know there is always more to the story.
Bullboard Posts